DEFA6: A Potential Drug Target and Biomarker (G1671)

Target Name: DEFA6

NCBI ID: G1671

DEFA6

DEFA6: A Potential Drug Target and Biomarker

DEFA6 is a gene that encodes a protein involved in the development and maintenance of blood vessels. The protein, also known as dfna6, has been shown to play a crucial role in the formation of new blood vessels, which is a critical process in the development and progression of many diseases, including cardiovascular diseases.

Recent studies have identified dfna6 as a potential drug target and biomarker for a variety of diseases, including cardiovascular diseases, neurodegenerative disorders, and cancer. In this article, we will explore the potential of dfna6 as a drug target and biomarker, and discuss the current research on its potential clinical applications.

Potential Drug Target

The potential drug target for dfna6 is based on its role in the development and maintenance of blood vessels. dfna6 has been shown to promote the formation of new blood vessels, which is a critical process in the development and progression of many diseases.

One of the key mechanisms by which dfna6 promotes blood vessel formation is through the regulation of angiogenesis, which is the process by which new blood vessels are formed. dfna6 has been shown to play a key role in this process by regulating the growth and differentiation of blood vessels, as well as the production of new blood cells.

In addition to its role in blood vessel formation, dfna6 has also been shown to play a key role in the regulation of blood pressure. Studies have shown that dfna6 plays a critical role in the regulation of blood pressure by controlling the production of nitric oxide, a molecule that causes blood vessels to relax and widen.

Potential Biomarker

The potential use of dfna6 as a biomarker for a variety of diseases is based on its role in the regulation of blood vessels and blood pressure. dfna6 has been shown to be involved in the regulation of blood pressure by controlling the production of nitric oxide. This is a critical molecule that causes blood vessels to relax and widen, which can lead to lower blood pressure.

In addition to its role in blood pressure regulation, dfna6 has also been shown to be involved in the regulation of blood vessel growth and differentiation. Studies have shown that dfna6 plays a critical role in the growth and development of blood vessels, as well as the production of new blood cells.

Potential clinical applications

The potential use of dfna6 as a drug target and biomarker for a variety of diseases is based on its role in the development and maintenance of blood vessels, as well as its ability to regulate blood pressure and blood cell formation.

One potential clinical application for dfna6 is the treatment of cardiovascular diseases. Studies have shown that dfna6 plays a critical role in the development and progression of cardiovascular diseases, including heart failure, hypertension, and stroke. By targeting dfna6 with drugs, it may be possible to improve blood vessel formation and reduce the risk of cardiovascular diseases.

Another potential clinical application for dfna6 is the treatment of neurodegenerative disorders. Studies have shown that dfna6 is involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. By targeting dfna6 with drugs, it may be possible to slow down or reverse the progression of these disorders.

In addition to its potential clinical applications, dfna6 has also been shown to be a potential biomarker for a variety of other diseases, including cancer. Studies have shown that dfna6 is involved in the regulation of cancer cell growth and

Protein Name: Defensin Alpha 6

Functions: Host-defense peptide that contributes to intestinal innate immunity and mediates homeostasis at mucosal surfaces by forming higher-order oligomers that capture bacteria and prevent microbial invasion of the epithelium (PubMed:15616305, PubMed:25158166, PubMed:25354318, PubMed:28026958, PubMed:17088326). After binding to bacterial surface proteins, undergoes ordered self-assembly to form fibril-like nanonets that surround and entangle bacteria and thereby prevent bacterial invasion across the epithelial barrier (PubMed:22722251). Entangles and agglutinates Gram-negative bacteria, such as E.coli, S.typhimurium and Y.enterocolitica, and Gram-positive bacteria such as L.monocytogenes, thereby protecting the intestine against invasion by enteric bacterial pathogens (PubMed:27076903, PubMed:25158166, PubMed:22722251). Blocks adhesion of C.albicans to intestinal epithelial cells and thereby suppresses fungal invasion of epithelial cells and biofilm formation (PubMed:28026958). Under reducing conditions and in an acidic environment similar to the intestinal milieu, exhibits inhibitory activity against anaerobic bacteria such as B.adolescentis, L.acidophilus and B.breve, as well as B.longum and S.thermophilus, possibly by leading to alterations in bacterial cell envelope structures (PubMed:25354318). The disulfide-linked oxidized form exhibits negligible antimicrobial activity against Gram-negative and Gram-positive bacteria, as compared to the enteric defensin DEFA5 (PubMed:15616305, PubMed:17088326)

The "DEFA6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFA6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets